B. infantis-based Formulation PBCLN-014

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable formulation containing the naturally occurring lactic acid-producing gut bacteria Bifidobacterium longum subspecies infantis (B. infantis), with potential immunomodulating activity. Upon oral administration, B. infantis-based formulation PBCLN-014 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the gastrointestinal (GI) tract and may re-establish a healthy microbiome in the GI tract. This may improve intestinal barrier function, suppress inflammation, enhance the patients' immunological activity and lower the risk of GI antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease (GvHD) in patients undergoing solid organ and allogeneic stem cell transplantation.

**Synonyms:** - Bifidobacterium longum Subspecies infantis-based Formulation PBCLN-014 - PBCLN 014 - PBCLN-014 - PBCLN014